gs3-10: "study of samuraciclib (ct7001), a first-in-class, oral, selective inhibitor of cdk7, in.."
Published 1 year ago • 125 plays • Length 15:13Download video MP4
Download video MP3
Similar videos
-
5:02
samuraciclib in combination with fulvestrant in patients with advanced hr /her2- breast cancer
-
9:15
gs1-06: "a randomized control phase iii trial of entinostat, a once weekly, class i selective..."
-
13:17
spotlight session: "three cdk 4/6 inhibitors, a lot of biomarkers, what does it all mean moving..."
-
12:11
gs3-09: "loss of asxl1 tumor suppressor promotes resistance to cdk4/6 inhibitors in er breast..."
-
26:59
dr. david rimm | san antonio breast cancer symposium 2022 | general session
-
15:26
gs3-04: discussant
-
59:15
2021 san antonio breast cancer symposium update on mbc | 2021-2022 embrace mbc virtual forum series
-
33:35
dr. jennifer pietenpol | san antonio breast cancer symposium 2022
-
12:44
gs3-03: "genomic analysis of 733 her2 breast cancers identifies recurrent pathways alterations..."
-
13:10
dr. per karlsson | san antonio breast cancer symposium 2022 | general session
-
2:40
redefining the outcome of breast cancer surgery
-
1:29:40
ucsf bay area breast cancer forum: best of the 2021 san antonio breast cancer symposium
-
4:54
monarch 3 study: cdk4/6 inhibitors in the treatment of metastatic breast cancer
-
29:23
dr. shom goel |san antonio breast cancer symposium 2022 | year in review
-
1:08
head & neck cancer care with dr. joseph a. califano iii, otolaryngologist
-
10:25
gs3-06: "primary results of the ctrak tn trial: a clinical trial utilising ctdna mutation..."
-
1:51:16
dr. bora lim | challenging types of breast cancer | sabcs 2022 | education session
-
9:59
gs1-01: "phase 3 study of pembrolizumab chemotherapy vs placebo chemotherapy as neoadjuvant..."
-
9:17
dr. peter a. fasching | san antonio breast cancer symposium 2022 | general session